Organic Anion Transporting Polypeptide-Mediated Transport of, and Inhibition by, Asunaprevir, an Inhibitor of Hepatitis C Virus NS3 Protease-Reference-Cited by-同舟云学术

Organic Anion Transporting Polypeptide-Mediated Transport of, and Inhibition by, Asunaprevir, an Inhibitor of Hepatitis C Virus NS3 Protease

Published:2014-12-20 Issue:2 Volume:97 Page:159-166
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Eley T¹,Han Y-H¹,Huang S-P¹,He B¹,Li W¹,Bedford W¹,Stonier M¹,Gardiner D¹,Sims K¹,Rodrigues AD²,Bertz RJ¹

Affiliation:

1. Bristol-Myers Squibb; Research and Development; Princeton New Jersey USA

2. Pfizer; Research and Development; Groton Connecticut USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference26 articles.

1. Preclinical profile and characterization of the hepatitis C virus NS3 protease inhibitor asunaprevir (BMS-650032);McPhee;Antimicrob. Agents Chemother.,2012

2. The effect of hepatic impairment on the pharmacokinetics of asunaprevir, an HCV NS3 protease inhibitor;Eley;Antivir. Ther.,2014

3. Single and multiple ascending dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C;Pasquinelli;Antimicrob. Agents Chemother.,2012

4. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options;Suzuki;J. Hepatol.,2013

5. Asunaprevir (ASV; BMS-650032), an NS3 protease inhibitor, in combination with peginterferon and ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C infection;Bronowicki;J. Hepatol.,2012

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanistic Account of Distinct Change in Organic Anion Transporting Polypeptide 1B (OATP1B) Substrate Pharmacokinetics during OATP1B-Mediated Drug-Drug Interactions Using Physiologically Based Pharmacokinetic Modeling;Drug Metabolism and Disposition;2024-05-13

2. Mechanistic Determinants of Daprodustat Drug–Drug Interactions and Pharmacokinetics in Hepatic Dysfunction and Chronic Kidney Disease: Significance of OATP1B‐CYP2C8 Interplay;Clinical Pharmacology & Therapeutics;2024-02-26

3. The Role of CYPs and Transporters in the Biotransformation and Transport of the Anti-hepatitis C Antiviral Agents Asunaprevir, Daclatasvir, and Beclabuvir: Impact of Liver Disease, Race and Drug-drug Interactions on Safety and Efficacy;Current Drug Metabolism;2024-02

4. Mechanisms and Clinical Significance of Pharmacokinetic Drug Interactions Mediated by FDA and EMA-approved Hepatitis C Direct-Acting Antiviral Agents;Clinical Pharmacokinetics;2023-09-20

5. Drug transporters in drug disposition – the year 2022 in review;Drug Metabolism Reviews;2023-09-06